Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

H Ludwig; W Poenisch; S Knop; Alexander Egle; M Schreder; D Lechner; R Hajek; E Gunsilius; KJ Krenosz; A Petzer; K Weisel; D Niederwieser; H Einsele; W Willenbacher; Thomas Melchardt; Richard Greil; N Zojer

doi:10.1038/s41416-019-0581-8

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

H Ludwig, W Poenisch, S Knop, Alexander Egle (Co-author), M Schreder, D Lechner, R Hajek, E Gunsilius, KJ Krenosz, A Petzer, K Weisel, D Niederwieser, H Einsele, W Willenbacher, Thomas Melchardt (Co-author), Richard Greil (Co-author), N Zojer

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

17 Citations (Web of Science)

Original language	English
Pages (from-to)	751-757
Journal	BRITISH JOURNAL OF CANCER
Volume	121
Issue number	9
DOIs	https://doi.org/10.1038/s41416-019-0581-8
Publication status	Published - 2019

Keywords

ORAL PROTEASOME INHIBITOR
HIGH-RISK CYTOGENETICS
PLUS POMALIDOMIDE
SURVIVAL OUTCOMES
TRIAL
LENALIDOMIDE
DARATUMUMAB
BORTEZOMIB
DISEASE
GAIN

Access to Document

10.1038/s41416-019-0581-8

Cite this

Ludwig, H., Poenisch, W., Knop, S., Egle, A., Schreder, M., Lechner, D., Hajek, R., Gunsilius, E., Krenosz, KJ., Petzer, A., Weisel, K., Niederwieser, D., Einsele, H., Willenbacher, W., Melchardt, T., Greil, R., & Zojer, N. (2019). Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. BRITISH JOURNAL OF CANCER , 121(9), 751-757. https://doi.org/10.1038/s41416-019-0581-8

Ludwig, H ; Poenisch, W ; Knop, S et al. / Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. In: BRITISH JOURNAL OF CANCER 2019 ; Vol. 121, No. 9. pp. 751-757.

@article{71d9e7f797c345f4a365e5359ce81913,

title = "Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma",

keywords = "ORAL PROTEASOME INHIBITOR, HIGH-RISK CYTOGENETICS, PLUS POMALIDOMIDE, SURVIVAL OUTCOMES, TRIAL, LENALIDOMIDE, DARATUMUMAB, BORTEZOMIB, DISEASE, GAIN",

author = "H Ludwig and W Poenisch and S Knop and Alexander Egle and M Schreder and D Lechner and R Hajek and E Gunsilius and KJ Krenosz and A Petzer and K Weisel and D Niederwieser and H Einsele and W Willenbacher and Thomas Melchardt and Richard Greil and N Zojer",

note = "Egle; Melchardt; Greil: Paracelsus Med Univ, LIMCR, SCRI,Canc Cluster Salzburg,Oncol Ctr, Dept Internal Med Haematol Med Oncol Hemostaseol, Salzburg, Austria; Lehr KH: Lechner: Ordensklinikum Linz Elisabethinen, Dept Med Hematol Stem Cell Transplantat Hemostase, Linz, Austria; Petzer: Ordensklinikum Linz Barmherzige Schwestern, Dept Internal Med 1, Linz, Austria;",

year = "2019",

doi = "10.1038/s41416-019-0581-8",

language = "English",

volume = "121",

pages = "751--757",

journal = "BRITISH JOURNAL OF CANCER ",

issn = "0007-0920",

publisher = "Springer Nature",

number = "9",

}

Ludwig, H, Poenisch, W, Knop, S, Egle, A, Schreder, M, Lechner, D, Hajek, R, Gunsilius, E, Krenosz, KJ, Petzer, A, Weisel, K, Niederwieser, D, Einsele, H, Willenbacher, W, Melchardt, T , Greil, R & Zojer, N 2019, 'Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma', BRITISH JOURNAL OF CANCER , vol. 121, no. 9, pp. 751-757. https://doi.org/10.1038/s41416-019-0581-8

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. / Ludwig, H; Poenisch, W; Knop, S et al.
In: BRITISH JOURNAL OF CANCER , Vol. 121, No. 9, 2019, p. 751-757.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

AU - Ludwig, H

AU - Poenisch, W

AU - Knop, S

AU - Egle, Alexander

AU - Schreder, M

AU - Lechner, D

AU - Hajek, R

AU - Gunsilius, E

AU - Krenosz, KJ

AU - Petzer, A

AU - Weisel, K

AU - Niederwieser, D

AU - Einsele, H

AU - Willenbacher, W

AU - Melchardt, Thomas

AU - Greil, Richard

AU - Zojer, N

N1 - Egle; Melchardt; Greil: Paracelsus Med Univ, LIMCR, SCRI,Canc Cluster Salzburg,Oncol Ctr, Dept Internal Med Haematol Med Oncol Hemostaseol, Salzburg, Austria; Lehr KH: Lechner: Ordensklinikum Linz Elisabethinen, Dept Med Hematol Stem Cell Transplantat Hemostase, Linz, Austria; Petzer: Ordensklinikum Linz Barmherzige Schwestern, Dept Internal Med 1, Linz, Austria;

PY - 2019

Y1 - 2019

KW - ORAL PROTEASOME INHIBITOR

KW - HIGH-RISK CYTOGENETICS

KW - PLUS POMALIDOMIDE

KW - SURVIVAL OUTCOMES

KW - TRIAL

KW - LENALIDOMIDE

KW - DARATUMUMAB

KW - BORTEZOMIB

KW - DISEASE

KW - GAIN

U2 - 10.1038/s41416-019-0581-8

DO - 10.1038/s41416-019-0581-8

M3 - Original Article

C2 - 31558804

SN - 0007-0920

VL - 121

SP - 751

EP - 757

JO - BRITISH JOURNAL OF CANCER

JF - BRITISH JOURNAL OF CANCER

IS - 9

ER -

Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D et al. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. BRITISH JOURNAL OF CANCER . 2019;121(9):751-757. doi: 10.1038/s41416-019-0581-8